Comparative Pharmacology
Head-to-head clinical analysis: ATOMOXETINE HYDROCHLORIDE versus QELBREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOMOXETINE HYDROCHLORIDE versus QELBREE.
ATOMOXETINE HYDROCHLORIDE vs QELBREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective norepinephrine reuptake inhibitor (NRI) that increases noradrenergic neurotransmission in the prefrontal cortex.
Qelbree (viloxazine) is a selective norepinephrine reuptake inhibitor (NRI) believed to exert its therapeutic effects by increasing norepinephrine levels in the prefrontal cortex, which enhances attention and reduces impulsivity/hyperactivity.
Initial 40 mg orally once daily; increase after minimum 3 days to 80 mg/day; maximum 100 mg/day if inadequate response after 2-4 weeks.
Initial: 0.5 mg orally once daily. Titrate by 0.5 mg increments every 2-3 days based on efficacy and tolerability to a maximum dose of 4 mg once daily. Target dose 2-4 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours in CYP2D6 extensive metabolizers; in poor metabolizers, half-life is prolonged to about 21-24 hours.
Terminal elimination half-life is approximately 14-17 hours in adults, supporting once-daily dosing. Steady-state is achieved within 7 days.
Primarily renal: approximately 80% of a dose is excreted in urine, with 2-3% as unchanged drug; 17% fecal.
Primarily hepatic metabolism (CYP3A4-mediated) with <1% excreted unchanged in urine. Fecal elimination accounts for ~55% of the dose as metabolites; renal excretion accounts for ~40% as metabolites.
Category C
Category C
Norepinephrine Reuptake Inhibitor
Norepinephrine Reuptake Inhibitor